Key result
Doxorubicin treatment increased the cumulative incidence of congestive heart failure to 26% at a cumulative dose of 550 mg/m2 in a cohort of 630 patients.
Why the study?
What is the incidence of doxorubicin-related congestive heart failure at various cumulative doses in patients with cancer?
Population
Patients with breast carcinoma or small cell lung carcinoma
Design
Cohort, Patients were randomized to a doxorubicin-plus-placebo arm of three…
Authors
Loading...
Doxorubicin-related CHF may occur more frequently than prior estimates suggest; challenges consensus and leaves open prospective validation of monitoring.
Cohort (n=630)
null
null
Yes
What is the incidence of doxorubicin-related congestive heart failure at various cumulative doses in patients with cancer?
Effect estimate: null (95% CI null)
p-value: p=null
Doxorubicin-induced heart failure occurs at a significantly higher rate (26% at 550 mg/m2) than previously recognized, and standard LVEF monitoring may inadequately predict its onset.
Swain et al. (2003) conducted a cohort in doxorubicin-related congestive heart failure (n=630). Doxorubicin vs. Placebo was evaluated on Doxorubicin-related congestive heart failure (null, 95% CI null, p=null). Doxorubicin treatment increased the cumulative incidence of congestive heart failure to 26% at a cumulative dose of 550 mg/m2 in a cohort of 630 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: